TrxR1 Cancer Research Results

TrxR1, thioredoxin reductase 1: Click to Expand ⟱
Source:
Type:
TrxR1 or TXNRD1 (Thioredoxin Reductase 1)
Redox Control, Stress Tolerance, and Therapy Resistance
• Many studies have found that an elevated expression of TrxR1 in breast tumors, NSCLC, HCC correlates with increased tumor aggressiveness and a poorer prognosis.
-TrxR1 expression was elevated by >50 fold in FaDu and HeLa cells, and by >20 fold in SCC-1 compared to either MSK-Leuk1 or keratinocytes.

High TXNRD1 expression often associates with:
-Advanced stage
-Therapy resistance
-Reduced survival

TrxR1 Inhibition
-Collapses redox control
-Causes rapid ROS accumulation
-Triggers apoptosis, especially in high-stress tumors


Scientific Papers found: Click to Expand⟱
5862- carbop,  Cisplatin,    Molecular Mechanisms of Resistance and Toxicity Associated with Platinating Agents
- Review, Var, NA
DNAdam↑, It is generally agreed that DNA is the preferential and cytotoxic target for cisplatin and other platinating agents. able to induce similar numbers of single-strand and double-strand breaks on DNA
ER Stress↑, shown to cause activation of apoptotic caspases through activation of the endoplasmic reticulum (ER) stress pathway (
UPR↑, When the ER experiences stress such as starvation or treatment with inhibitors of N-glycosylation (e.g. tunicamycin), it cannot fold or transport proteins correctly, and the UPR is activated.
ATF4↑, regulatory components of the ER stress pathway, including ATF4, ATF6, XBP1, and BiP (Grp78), are upregulated
ATF6↑,
XBP-1↑,
GRP78/BiP↑,
NP/CIPN↝, Carboplatin is notably less neurotoxic than cisplatin at conventional doses, with a similar sensory neuropathy occurring in approximately 6% of patients
toxicity↝, Carboplatin rarely results in nephrotoxicity and peripheral neuropathy, with its major toxicity being myelosuppression
eff↑, exposure to buthiomine sulfoximine (BSO), which significantly depleted cellular glutathione concentration, resulted in a significant enhancement in cisplatin cytotoxicity [151].
TrxR1⇅, Both cisplatin and transplatin show this inhibition of TxrR1 [161], as does oxaliplatin but not carboplatin [162]


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

TrxR1⇅, 1,  

Protein Folding & ER Stress ⓘ

ATF6↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,  

Angiogenesis & Vasculature ⓘ

ATF4↑, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Functional Outcomes ⓘ

NP/CIPN↝, 1,   toxicity↝, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TrxR1, thioredoxin reductase 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1207  State#:%  Dir#:3
  wNotes=on  sortOrder:rid,rpid

 

Home Page